According to Galmed Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2023 the company had a P/S ratio of N/A.
Year | P/S ratio | Change |
---|---|---|
2023 | N/A | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | -100% |
2018 | 70.4 | -39.12% |
2017 | 116 | 26.72% |
2016 | 91.3 | |
2015 | N/A | |
2014 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Evoke Pharma
EVOK | 0.7708 | N/A | ๐บ๐ธ USA |
Endo International
ENDPQ | 0.0001 | N/A | ๐ฎ๐ช Ireland |
Aerie Pharmaceuticals AERI | 3.52 | N/A | ๐บ๐ธ USA |
Catalent CTLT | 2.46 | N/A | ๐บ๐ธ USA |